Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
22/05/2024 | 15:06 | Edgar (US Regulatory) | Form SC 14D9/A - Solicitation, recommendation statements: [Amend] | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
22/05/2024 | 13:01 | Edgar (US Regulatory) | Form SC TO-T/A - Tender offer statement by Third Party: [Amend] | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
13/05/2024 | 12:32 | Edgar (US Regulatory) | Form SC 14D9 - Solicitation, recommendation statements | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
13/05/2024 | 12:31 | Edgar (US Regulatory) | Form SC TO-T - Tender offer statement by Third Party | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
10/05/2024 | 13:27 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
06/05/2024 | 23:16 | Edgar (US Regulatory) | Form SC TO-C - Written communication relating to an issuer or third party | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
29/04/2024 | 13:00 | Business Wire | Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
09/04/2024 | 13:00 | Business Wire | Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
27/02/2024 | 13:00 | Business Wire | Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
20/02/2024 | 22:05 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
14/02/2024 | 22:06 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
07/02/2024 | 13:52 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
07/02/2024 | 13:11 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
06/02/2024 | 13:10 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
06/02/2024 | 13:00 | Business Wire | Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
01/02/2024 | 22:50 | Business Wire | Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024 | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
01/02/2024 | 13:00 | Business Wire | Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
18/01/2024 | 17:13 | Business Wire | Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
08/01/2024 | 13:00 | Business Wire | Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
05/01/2024 | 13:00 | Business Wire | Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18 | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
02/01/2024 | 13:00 | Business Wire | Deciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
01/12/2023 | 00:05 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
29/11/2023 | 13:00 | Business Wire | Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
30/10/2023 | 12:01 | Business Wire | Deciphera Pharmaceuticals Announces Third Quarter 2023 Financial Results | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
30/10/2023 | 12:00 | Business Wire | Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2 Study of Vimseltinib in TGCT | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
29/09/2023 | 15:00 | PR Newswire (US) | Medison Pharma Announces Public Formulary Listing of QINLOCK® (ripretinib) in Canadian Provinces: Ontario and Quebec for Advanced Gastrointestinal Stromal Tumor (GIST) Treatment | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
15/09/2023 | 23:00 | Business Wire | Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
05/09/2023 | 22:15 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
09/08/2023 | 13:00 | Business Wire | Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
03/08/2023 | 22:15 | Business Wire | Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |